Compare GFR & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFR | DNA |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.7M | 835.7M |
| IPO Year | 2023 | 2020 |
| Metric | GFR | DNA |
|---|---|---|
| Price | $6.85 | $9.99 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 3 | 3 |
| Target Price | $7.87 | ★ $8.00 |
| AVG Volume (30 Days) | 1.2M | ★ 3.5M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $78.80 | $13.05 |
| P/E Ratio | $4.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.15 | $5.37 |
| 52 Week High | $7.16 | $18.22 |
| Indicator | GFR | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 46.58 |
| Support Level | $5.54 | $6.75 |
| Resistance Level | $6.94 | $10.45 |
| Average True Range (ATR) | 0.27 | 1.56 |
| MACD | 0.08 | -0.43 |
| Stochastic Oscillator | 95.83 | 3.46 |
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations. The company is actively developing its Hangingstone Facilities using SAGD, an enhanced oil recovery extraction method.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.